Adverse effects of proton pump inhibitors;Efectos adversos de los inhibidores de la bomba de protones

Acta Gastroenterologica Latinoamericana

Volumn 39, Issue 3, 2009, Pages 219-222

  Doweck, Judith ^a  

^a HOSPITAL DE GASTROENTEROLOGÍA DR CARLOS BONORINO UDAONDO   (Argentina)

Author keywords

[No Author keywords available]

Indexed keywords

CYANOCOBALAMIN; PROTON PUMP INHIBITOR;

CAMPYLOBACTER; CAMPYLOBACTERIOSIS; CENTRAL NERVOUS SYSTEM DISEASE; CLOSTRIDIUM DIFFICILE; COMMUNITY ACQUIRED PNEUMONIA; CYANOCOBALAMIN DEFICIENCY; EPIDEMIC; ESCHERICHIA COLI; ESCHERICHIA COLI INFECTION; GASTROINTESTINAL POLYPOSIS; HELICOBACTER PYLORI; HUMAN; INFECTION RISK; KIDNEY DISEASE; LONG TERM CARE; NOTE; NUTRITIONAL DEFICIENCY; SALMONELLA; SALMONELLOSIS; SHIGELLA; STOMACH FUNDUS;

EID: 70349765862     PISSN: 03009033     EISSN: 03009033     Source Type: Journal    
DOI: None     Document Type: Note

References (22)

1. Schenk BE, Kuipers EJ, Nelis GF, et al. Effect of Helicobacter pylori eradication on chronic gastritis during ompeprazole therapy. Gut 2000;46:615-621. (Pubitemid 30305777)
2. Malfertheiner P, Megraud F, O'Morain C, et al. Current concepts in management of Helicobacter pylori infection: the Maastricht III Consensus Report. Gut 2007;56:772-781. (Pubitemid 46854190)
3. Hakanson R, Bottcher G, Sundler F, et al. Activation and hyperplasia of gastrin and enterochromaffin-like cells in the stomach. Digestion 1986;35:23-41. (Pubitemid 17197932)
4. Robinson M. Review article: current perspectives on hypergastrinemia and enterochromaffin-like-cell hyperplasia. Aliment Pharmacol Ther 1999;13:5-10. (Pubitemid 29467291)
5. Leonard J, Marchall JK, Moayyedi P. Systematic review of the risk of enteric infection in patients taking acid suppression. Am J Gastroenterol 2007;102:2047-2056. (Pubitemid 47301504)
6. Lahheij RJ, Sturkenboom MC. Risk of community acquired pneumonia and use of gastric acid-suppressive drugs. JAMA 2004;292:1955-1960.
7. Festen HP. Intrinsic factor secretion and cobalamin absorption. Physiology and pathophysiology in the gastrointestinal tract. Scand J Gastroenterol 1991;188:1-7.
8. Howden CW. Vitamin B12 levels during prolonged treatment with proton pump inhibitors. J Clin Gastroenterol 2000;30:29-33. (Pubitemid 30032651)
9. Yang YX, Lewis JD, Epstein S, et al. Long-term proton pump inhibitor therapy and risk of hip fracture. JAMA 2006;296:2947-2953. (Pubitemid 46021498)
10. Vestergaard P, Rejnmark L, Mosekilde L. Proton pump inhibitors, histamine H2 receptor antagonists, and other antacid medications and the risk of fracture. Calcif Tissue Int 2006;79:76-83. (Pubitemid 44306164)
11. Polimeni G, Cutroneo P, Gallo A, et al. Rabeprazole and psychiatric symptoms. Ann Pharmacother 2007;41:1315-1317.
12. Roesler R, Henriques JA, Schwartsmann G. Gastrin-releasing peptide receptor as a molecular target for psychiatric and neurologic disorders. CNS Neurol Disord Drug Targets 2006;5:197-204. (Pubitemid 43796620)
13. Harmark L, van der Wiel HE, de Groot MC, et al. Proton pump inhibitor-induced acute interstitial nephritis. Br J Clin Pharmacol 2007;64:819-823. (Pubitemid 350222055)
14. Simpson IJ, Marshall MR, Pilmore H, et al. Proton pump inhibitors and acute interstitial nephritis: report and analysis of 15 cases. Nephrology (Carlton) 2006;11:381-385. (Pubitemid 44470084)
15. Dubberke ER, Reske KA, Yan Y, et al. Clostridium difficile-associated disease in a setting of endemicity: identification of novel risk factors. Clin Infect Dis 2007;45:1543-1549.
16. Lowe DO, Mamdani MM, Kopp A, et al. Proton pump inhibitors and hospitalization for Clostridium difficile-associated disease: a population-based study. Clin Inf Dis 2006;43:1272-1276. (Pubitemid 44706452)
17. Pepin J, Saheb N, Coulombe MA, et al. Emergence of fluoroquinolones as the predominant risk factor for Clostridium difficile-associated diarrhea: a cohort study during an epidemic in Quebec. Clin Inf Dis 2005;41:1254-1260. (Pubitemid 41532667)
18. Raghunath AS, O'Morain C, McLoughlin RC, Review article. The long term use of proton-pump inhibitors. Alilment Pharmacol Ther 2005;22:55-63.
19. Iida M, Yao T, Watanbe H, Imamura K, Fuyuno S, Omae T. Spontaneous disappearance of fundic gland polyposis: report of three cases. Gastroenterology 1980;79:725-728. (Pubitemid 10009565)
20. Fossmark R, Jianu CS, Martinsen TC, Qvigstad G, Syversen U, Waldum HI. Serum gastrin and chromogranin A levels in patients with fundic gland polyps caused by long term proton-pump inhibition. Scand J Gastroenterol 2008;43:20-24.
21. Robertson DJ, Larson H, Frils S, Pedersen L, Baron JA, Sorensen HT. Proton pump inhibitor use and risk of colorectal. cancer: a population-based case-control study. Gastroenterology 2007;133:755-760. (Pubitemid 47385871)
22. Yang YX, Hennessy S, Propert K, Hwang WT, Sedarat A, Lewis JD. Chronic proton pump inhibitor therapy and the risk of colorectal cancer. Gastroenterology 2007;133:748-754. (Pubitemid 47374135)